非小细胞-话题@MedSci

#非小细胞#

746篇内容 | 6355人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2060086, encodeId=bfe02060086d8, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, objectType=article, longId=295254, objectId=ccd329525402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd329525402, replyNumber=0, likeNumber=83, createdTime=2022-03-01, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd329525402, moduleTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccd329525402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060121, encodeId=a3b92060121aa, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后, objectType=article, longId=727471, objectId=cd20e27471d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd20e27471d6, replyNumber=0, likeNumber=80, createdTime=2022-07-31, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd20e27471d6, moduleTitle=J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd20e27471d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060026, encodeId=c6f22060026aa, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Clin Lung Cancer: Atezolizumab联合ipilimumab治疗经治的驱动基因阴性的晚期非小细胞肺癌（NSCLC）的安全性和疗效, objectType=article, longId=217906, objectId=3f8521e906e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f8521e906e5, replyNumber=0, likeNumber=52, createdTime=2022-02-04, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f8521e906e5, moduleTitle=Clin Lung Cancer: Atezolizumab联合ipilimumab治疗经治的驱动基因阴性的晚期非小细胞肺癌（NSCLC）的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f8521e906e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060108, encodeId=220d20601081c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, objectType=article, longId=302214, objectId=fba0302214dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fba0302214dc, replyNumber=0, likeNumber=125, createdTime=2023-02-11, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fba0302214dc, moduleTitle=2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fba0302214dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060107, encodeId=ca90206010eac, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, objectType=article, longId=302210, objectId=5b43302210bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b43302210bd, replyNumber=0, likeNumber=99, createdTime=2022-11-17, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b43302210bd, moduleTitle=2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b43302210bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060079, encodeId=126b20600e915, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后, objectType=article, longId=294620, objectId=03df29462025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03df29462025, replyNumber=0, likeNumber=90, createdTime=2022-05-12, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03df29462025, moduleTitle=Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03df29462025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060120, encodeId=1cf920601209f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L, objectType=article, longId=726654, objectId=865fe2665466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=865fe2665466, replyNumber=0, likeNumber=76, createdTime=2022-05-16, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=865fe2665466, moduleTitle=Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=865fe2665466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060066, encodeId=cfed206006626, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, objectType=article, longId=221343, objectId=6363221343dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6363221343dc, replyNumber=0, likeNumber=79, createdTime=2022-09-27, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6363221343dc, moduleTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6363221343dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060011, encodeId=141720600115f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=The Oncologist：免疫治疗治疗转移性非小细胞肺癌的疗效：中东欧国家的真实世界数据, objectType=article, longId=215462, objectId=f5b321546205, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5b321546205, replyNumber=0, likeNumber=77, createdTime=2021-09-02, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5b321546205, moduleTitle=The Oncologist：免疫治疗治疗转移性非小细胞肺癌的疗效：中东欧国家的真实世界数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5b321546205)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060057, encodeId=c31d206005e75, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, objectType=article, longId=220865, objectId=1061220865c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1061220865c1, replyNumber=0, likeNumber=96, createdTime=2022-10-23, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1061220865c1, moduleTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1061220865c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060020, encodeId=d56e2060020db, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据, objectType=article, longId=217082, objectId=044321e0828e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=044321e0828e, replyNumber=0, likeNumber=73, createdTime=2021-12-18, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=044321e0828e, moduleTitle=君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=044321e0828e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060129, encodeId=0917206012924, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, objectType=article, longId=728863, objectId=e46de28863d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46de28863d9, replyNumber=0, likeNumber=0, createdTime=2022-11-29, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46de28863d9, moduleTitle=J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46de28863d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060116, encodeId=50222060116d0, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Nat Med：血源性肿瘤突变负担作为非小细胞肺癌阿特珠单抗治疗的生物标志物, objectType=article, longId=724549, objectId=b40de24549be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40de24549be, replyNumber=0, likeNumber=72, createdTime=2022-07-25, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40de24549be, moduleTitle=Nat Med：血源性肿瘤突变负担作为非小细胞肺癌阿特珠单抗治疗的生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b40de24549be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060111, encodeId=124c2060111f6, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后, objectType=article, longId=723788, objectId=3020e23788de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3020e23788de, replyNumber=0, likeNumber=85, createdTime=2023-03-22, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3020e23788de, moduleTitle=BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3020e23788de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060021, encodeId=45a32060021e6, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=【直播】上海市胸科医院张波全面解读：EGFR突变晚期非小细胞肺癌的诊疗进展, objectType=article, longId=217030, objectId=d87e21e03024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d87e21e03024, replyNumber=0, likeNumber=38, createdTime=2022-03-02, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d87e21e03024, moduleTitle=【直播】上海市胸科医院张波全面解读：EGFR突变晚期非小细胞肺癌的诊疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d87e21e03024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060018, encodeId=e1f32060018f7, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Lung Cancer： XPO1突变对转移性非小细胞肺癌（NSCLC）的生存影响, objectType=article, longId=216918, objectId=165b21691839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=165b21691839, replyNumber=0, likeNumber=70, createdTime=2022-08-05, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=165b21691839, moduleTitle=Lung Cancer： XPO1突变对转移性非小细胞肺癌（NSCLC）的生存影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=165b21691839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060053, encodeId=0a072060053a1, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察, objectType=article, longId=220773, objectId=9a41220e7350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a41220e7350, replyNumber=0, likeNumber=56, createdTime=2022-02-09, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a41220e7350, moduleTitle=贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a41220e7350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060023, encodeId=6b902060023a4, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=肌肉减少症会增加非小细胞癌患者术后复发风险, objectType=article, longId=217591, objectId=2b9b21e591d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b9b21e591d7, replyNumber=0, likeNumber=67, createdTime=2022-04-20, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b9b21e591d7, moduleTitle=肌肉减少症会增加非小细胞癌患者术后复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b9b21e591d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060036, encodeId=af4b206003617, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, objectType=article, longId=218842, objectId=20e9218842d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e9218842d0, replyNumber=0, likeNumber=67, createdTime=2022-03-18, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e9218842d0, moduleTitle=Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e9218842d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060067, encodeId=25ad206006e12, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, objectType=article, longId=221346, objectId=ab662213469b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab662213469b, replyNumber=0, likeNumber=91, createdTime=2022-10-26, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab662213469b, moduleTitle=FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab662213469b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非小细胞

2020-05-29

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效

2022-03-01

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后

2022-07-31

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Clin Lung Cancer: Atezolizumab联合ipilimumab治疗经治的驱动基因阴性的晚期非小细胞肺癌（NSCLC）的安全性和疗效

2022-02-04

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗

2023-02-11

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗

2022-11-17

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后

2022-05-12

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Lung Cancer：奥希替尼和阿法替尼交替治疗初治EGFR突变的晚期非小细胞肺癌（NSCLC）的疗效和安全性:WJOG10818L

2022-05-16

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性

2022-09-27

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

The Oncologist：免疫治疗治疗转移性非小细胞肺癌的疗效：中东欧国家的真实世界数据

2021-09-02

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析

2022-10-23

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

君实生物在世界肺癌大会（WCLC）首次发布特瑞普利单抗一线治疗非小细胞肺癌三期研究数据

2021-12-18

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

J Thorac Oncol: 奥希替尼+贝伐珠单抗对比奥希替尼治疗未治EGFR突变的非鳞状非小细胞肺癌患者的疗效：WJOG9717L研究

2022-11-29

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Nat Med：血源性肿瘤突变负担作为非小细胞肺癌阿特珠单抗治疗的生物标志物

2022-07-25

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

BMC Cancer：局部晚期非小细胞肺癌（LA-NSCLC）放化疗后durvalumab治疗可改善患者的预后

2023-03-22

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

【直播】上海市胸科医院张波全面解读：EGFR突变晚期非小细胞肺癌的诊疗进展

2022-03-02

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Lung Cancer： XPO1突变对转移性非小细胞肺癌（NSCLC）的生存影响

2022-08-05

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

贝伐珠单抗治疗非小细胞肺癌脑转移瘤放射治疗后难治性瘤周水肿疗效观察

2022-02-09

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

肌肉减少症会增加非小细胞癌患者术后复发风险

2022-04-20

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Cancer Commun：中国KRAS突变型非小细胞肺癌患者化疗后的临床特点及预后分析

2022-03-18

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

FDA批准百时美施贵宝的PD-1单抗Opdivo和CTLA-4单抗Yervoy组合，一线治疗非小细胞肺癌

2022-10-26

科室
- - 订阅+
  - 更多科室
工具
服务